Search

Your search keyword '"Steingo, Brian"' showing total 34 results

Search Constraints

Start Over You searched for: Author "Steingo, Brian" Remove constraint Author: "Steingo, Brian"
34 results on '"Steingo, Brian"'

Search Results

1. Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial

2. Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial

3. Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient- and physician-reported outcomes in relapsing multiple sclerosis: post hocanalyses of the EPOC trial

4. Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient- and physician-reported outcomes in relapsing multiple sclerosis: post hoc analyses of the EPOC trial.

5. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

7. Satralizumab Treatment in Adult Patients With AQP4-IgG–Seropositive Neuromyelitis Optica Spectrum Disorder: A Case Series (P13-5.010)

8. Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial

10. Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial

11. Long-term efficacy and safety of alemtuzumab in patients with RRMS: 12-year follow-up of CAMMS223

12. MSJ816612_supplementary_info – Supplemental material for Immune thrombocytopenia in alemtuzumab-treated MS patients: Incidence, detection, and management

13. MSJ881759_supplemental_material – Supplemental material for Efficacy of alemtuzumab over 6 years in relapsing–remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies

14. Efficacy of alemtuzumab over 6 years in relapsing–remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies

16. Immune thrombocytopenia in alemtuzumab-treated MS patients: Incidence, detection, and management

17. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis

18. Efficacy of alemtuzumab over 6 years in relapsing–remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies.

19. Immune thrombocytopenia in alemtuzumab-treated MS patients: Incidence, detection, and management.

20. Durable Efficacy and Safety With Alemtuzumab in CARE-MS I Patients Switching From SC IFNB-1a: 5-Year Follow-up (TOPAZ Study) (P6.366)

21. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

23. Durable Improvement in Clinical Outcomes in Patients With Relapsing-Remitting Multiple Sclerosis Who Discontinued SC IFNB-1a and Initiated Alemtuzumab: CARE-MS I Extension Study 4-Year Follow-up (P5.360)

24. Durable Efficacy of Alemtuzumab in CARE-MS II Patients With RRMS With Disease Activity (Relapse) Between Courses 1 and 2 (P5.349)

27. Emerging Challenges on the Therapeutic Landscape of Multiple Sclerosis: The Managed Care Physician's Perspective and Medical Director's Perspective.

29. Efficacy of alemtuzumab over 6 years in relapsing–remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies

30. Ofatumumab versus Teriflunomide in Multiple Sclerosis

31. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

32. Efficacy of alemtuzumab over 6 years in relapsing-remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies.

33. Long-term efficacy and safety of alemtuzumab in patients with RRMS: 12-year follow-up of CAMMS223.

34. Immune thrombocytopenia in alemtuzumab-treated MS patients: Incidence, detection, and management.

Catalog

Books, media, physical & digital resources